MAB5412
Anti-Indoleamine 2,3-dioxygenase Antibody, clone 10.1
clone 10.1, Chemicon®, from mouse
Synonym(s):
Indoleamine-pyrrole 2,3-dioxygenase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
10.1, monoclonal
species reactivity
human
species reactivity (predicted by homology)
mouse, rat
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG3
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... IDO1(3620)
General description
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
Specificity
Reacts with Indolamine 2,3-dioxygenase (IDO). Note IDO is usually expressed in response to various stimuli. A good positive control is HeLa cells stimulated with IFN-gamma, {http://www.upstate.com/browse/productdetail.q.ProductID.e.05-840#}.
Immunogen
Amino acids 78-184 of human IDO fused to GST.
Application
Anti-Indoleamine 2, 3-dioxygenase Antibody, clone 10.1 is an antibody against Indoleamine 2 for use in IH & WB.
Immunohistochemistry:
A previous lot of this antibody worked on lightly fixed tissues; Triton X-100 treatment only in the block, not with primary antibody. High temperature antigen retrieval is recommended.
Western blot:
Recognizes a 42-45kDa band in IFN-gamma treated human HeLa cell lines. Mouse IDO runs slightly smaller in blots than human IDO.
Optimal working dilutions must be determined by end user.
A previous lot of this antibody worked on lightly fixed tissues; Triton X-100 treatment only in the block, not with primary antibody. High temperature antigen retrieval is recommended.
Western blot:
Recognizes a 42-45kDa band in IFN-gamma treated human HeLa cell lines. Mouse IDO runs slightly smaller in blots than human IDO.
Optimal working dilutions must be determined by end user.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Inflammation & Autoimmune Mechanisms
Inflammation & Autoimmune Mechanisms
Quality
Routinely evaluated by Western Blot on untreated and IFNgamma treated HeLa lysates.
Western blot:
1:500 dilution of this lot detected IDO on 10 μg of untreated and IFN gamma treated HeLa lysates.
Western blot:
1:500 dilution of this lot detected IDO on 10 μg of untreated and IFN gamma treated HeLa lysates.
Target description
42-45kDa
Linkage
Replaces: AB5968
Physical form
Format: Purified
Protein A purified
Purified mouse monoclonal IgG3 in buffer containing 0.02 M phosphate, 0.25 M NaCl, 0.1% NaN3, pH 7.6.
Storage and Stability
Stable for 6 months at 2-8ºC in undiluted aliquots from date of receipt.
Analysis Note
Control
IFN-gamma stimulated human peripheral blood lymphocytes, HeLa lysates.
IFN-gamma stimulated human peripheral blood lymphocytes, HeLa lysates.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Davide Matino et al.
The Journal of clinical investigation, 125(10), 3766-3781 (2015-10-02)
The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore
Sung Hoon Sim et al.
Cancer science, 103(2), 155-160 (2011-11-24)
There is no specific marker to evaluate the immuno-suppressive status of cancer patients. Several markers, such as CD124, latency-associated peptide (LAP), arginase I, indole-amine-2,3-dioxygenase (IDO) and inducible nitric oxide synthase (iNOS), are known to be associated with immune suppression. However
Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes.
Maliniemi, P; Hahtola, S; Ovaska, K; Jeskanen, L; Vakeva, L; Jantti, K; Stadler et al.
Orphanet Journal of Rare Diseases null
Antonio Curti et al.
Blood, 109(7), 2871-2877 (2006-12-14)
Indoleamine 2,3-dioxygenase (IDO) is a novel immunosuppressive agent expressed in some subsets of normal and neoplastic cells, including acute myeloid leukemia (AML) cells. Here, we show that IDO expression correlates with increased circulating CD4+CD25+FOXP3+ T cells in patients with AML
Hatem Soliman et al.
Cancer immunology, immunotherapy : CII, 62(5), 829-837 (2013-01-25)
The immunosuppressive enzyme, indoleamine 2,3 dioxygenase (IDO), is overexpressed in many different tumor types including breast cancer. IDO inhibitors synergize with chemotherapy in breast cancer murine models. Characterizing IDO expression in breast cancer could define which patients receive IDO inhibitors.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service